Dergi makalesi Açık Erişim

Preferential production of IgG1, IL-4 and IL-10 in MuSK-immunized mice

Ulusoy, Canan; Kim, Eunmi; Tuzun, Erdem; Huda, Ruksana; Yilmaz, Vuslat; Poulas, Konstantinos; Trakas, Nikos; Skriapa, Lamprini; Niarchos, Athanasios; Strait, Richard T.; Finkelman, Fred D.; Turan, Selin; Zisimopoulou, Paraskevi; Tzartos, Socrates; Saruhan-Direskeneli, Guher; Christadoss, Premkumar


MARC21 XML

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="http://www.loc.gov/MARC21/slim">
  <leader>00000nam##2200000uu#4500</leader>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Kim, Eunmi</subfield>
    <subfield code="u">Univ Texas Med Branch, Dept Microbiol &amp; Immunol, Galveston, TX 77555 USA</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Tuzun, Erdem</subfield>
    <subfield code="u">Istanbul Univ, Dept Neurosci, Expt Med Res Inst, TR-34393 Istanbul, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Huda, Ruksana</subfield>
    <subfield code="u">Univ Texas Med Branch, Dept Microbiol &amp; Immunol, Galveston, TX 77555 USA</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Yilmaz, Vuslat</subfield>
    <subfield code="u">Istanbul Univ, Istanbul Fac Med, Dept Physiol, TR-34393 Istanbul, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Poulas, Konstantinos</subfield>
    <subfield code="u">Univ Patras, Sch Hlth Sci, Dept Pharm, Patras 26504, Greece</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Trakas, Nikos</subfield>
    <subfield code="u">Hellenic Pasteur Inst, Athens 11521, Greece</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Skriapa, Lamprini</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Niarchos, Athanasios</subfield>
    <subfield code="u">Univ Patras, Sch Hlth Sci, Dept Pharm, Patras 26504, Greece</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Strait, Richard T.</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Finkelman, Fred D.</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Turan, Selin</subfield>
    <subfield code="u">Istanbul Univ, Dept Neurosci, Expt Med Res Inst, TR-34393 Istanbul, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Zisimopoulou, Paraskevi</subfield>
    <subfield code="u">Hellenic Pasteur Inst, Athens 11521, Greece</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Tzartos, Socrates</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Saruhan-Direskeneli, Guher</subfield>
    <subfield code="u">Istanbul Univ, Istanbul Fac Med, Dept Physiol, TR-34393 Istanbul, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Christadoss, Premkumar</subfield>
    <subfield code="u">Univ Texas Med Branch, Dept Microbiol &amp; Immunol, Galveston, TX 77555 USA</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="4">
    <subfield code="p">CLINICAL IMMUNOLOGY</subfield>
    <subfield code="v">151</subfield>
    <subfield code="n">2</subfield>
    <subfield code="c">155-163</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-tubitak-destekli-proje-yayinlari</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="a">Creative Commons Attribution</subfield>
    <subfield code="u">http://www.opendefinition.org/licenses/cc-by</subfield>
  </datafield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="a">10.1016/j.clim.2014.02.012</subfield>
    <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">Preferential production of IgG1, IL-4 and IL-10 in MuSK-immunized mice</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Ulusoy, Canan</subfield>
    <subfield code="u">Istanbul Univ, Dept Neurosci, Expt Med Res Inst, TR-34393 Istanbul, Turkey</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="o">oai:zenodo.org:63409</subfield>
    <subfield code="p">user-tubitak-destekli-proje-yayinlari</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="2">opendefinition.org</subfield>
    <subfield code="a">cc-by</subfield>
  </datafield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2014-01-01</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="u">https://aperta.ulakbim.gov.trrecord/63409/files/bib-bc8dd727-b578-4a8f-ad97-b518a462a4c7.txt</subfield>
    <subfield code="z">md5:abbd0171f9d75f85278acd474a85c50e</subfield>
    <subfield code="s">333</subfield>
  </datafield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  </datafield>
  <controlfield tag="005">20210316014001.0</controlfield>
  <controlfield tag="001">63409</controlfield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">publication</subfield>
    <subfield code="b">article</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness associated with acetylcholine receptor (AChR), muscle-specific receptor kinase (MuSK) or low-density lipoprotein receptor-related protein 4 (LRP4)-antibodies. MuSK-antibodies are predominantly of the non-complement fixing IgG4 isotype. The MuSK associated experimental autoimmune myasthenia gravis (EAMG) model was established in mice to investigate immunoglobulin (Ig) and cytokine responses related with MuSK immunity. C57BL/6 (B6) mice immunized with 30 mu g of recombinant human MuSK in incomplete or complete Freund's adjuvant (CFA) showed significant EAMG susceptibility (&amp;gt;80% incidence). Although mice immunized with 10 mu g of MuSK had lower EAMG incidence (14.3%), serum MuSK-antibody levels were comparable to mice immunized with 30 mu g MuSK. While MuSK immunization stimulated production of all antibody isotypes, non-complement fixing IgG1 was the dominant anti-MuSK Ig isotype in both sera and neuromuscular junctions. Moreover, MuSK immunized IgG1 knockout mice showed very low serum MuSK-antibody levels. Sera and MuSK-stimulated lymph node cell supernatants of MuSK immunized mice showed significantly higher levels of IL-4 and IL-10 (but not IFN-gamma and IL-12), than those of CFA immunized mice. Our results suggest that through activation of Th2-type cells, anti-MuSK immunity promotes production of IL-4, which in turn activates anti-MuSK IgG1, the mouse analog of human IgG4. These findings might provide clues for the pathogenesis of other IgG4-related diseases as well as development of disease specific treatment methods (e.g. specific IgG4 inhibitors) for MuSK-related MG. (c) 2014 Elsevier Inc. All rights reserved.</subfield>
  </datafield>
</record>
15
4
görüntülenme
indirilme
Görüntülenme 15
İndirme 4
Veri hacmi 1.3 kB
Tekil görüntülenme 14
Tekil indirme 4

Alıntı yap